Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study.

Jonathan CorrenMartin KarpeforsÅsa HellqvistJane R ParnesGene Colice

Published in: Journal of asthma and allergy (2021)

Tezepelumab reduced exacerbations across all seasons, irrespective of evaluated baseline disease characteristics. These data support the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled asthma.

Keyphrases

chronic obstructive pulmonary disease
lung function
cystic fibrosis
early onset
allergic rhinitis
electronic health record
drug induced
air pollution
artificial intelligence